Ignite Creation Date:
2024-05-06 @ 12:58 PM
Last Modification Date:
2024-10-26 @ 1:06 PM
Study NCT ID:
NCT03892525
Status:
TERMINATED
Last Update Posted:
2021-07-26
First Post:
2019-03-26
Brief Title:
Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell Lymphoma
Sponsor:
The Lymphoma Academic Research Organisation
Organization:
The Lymphoma Academic Research Organisation
Study Overview
Official Title:
Phase Ib Study Evaluating the Safety and Efficacy of Intratumoral Agonistic Anti-CD40 Selicrelumab in Combination With Anti-PDL1 Atezolizumab in Patients With Refractory or Relapsed B Cell Lymphoma
Status:
TERMINATED
Status Verified Date:
2021-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
End of drug development
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a multicenter open dose escalation phase Ib trial of intratumoral agonistic anti-CD40 Ab Selicrelumab intratumoral every 3 weeks for 3 cycles in combination with anti-PDL1 Ab Atezolizumab 1200mg intravenous every 3 weeks in patients with refractory or relapsed B cell lymphoma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None